EMCURE · Concall Summary
EMCURE PHARMACEUTICALS L
Emcure Pharmaceuticals Limited held its Q1 FY27 earnings conference call on August 6, 2026, where management provided updates on organizational changes and financial performance. CEO Satish Mehta announced that he would assume the role of Chairman following the retirement of Berjis Desai. The company reported a 22.8% year-on-year revenue growth to INR 2,580 crore, with EBITDA increasing by 25.8% to INR 508 crore. Profit after tax rose by 36.2% to INR 292 crore. The domestic business grew by 10.2%, while international markets saw a 34.2% increase in revenue. Management highlighted the acquisition of a 12.05% stake in Gennova, now a wholly owned subsidiary, and emphasized a focus on biosimilars. The call concluded with management expressing confidence in continued growth and operational improvements throughout FY27.
Management emphasized strong financial performance and strategic developments.
View source filing →Earlier concalls
- 2026-08-06 — Emcure Pharmaceuticals Limited reported its unaudited financial results for the quarter ended June 30, 2026, highlightin…
- 2026-06-12 — Emcure Pharmaceuticals Limited's investor presentation for June 2026 reported a total revenue of INR 9,204 crore for FY2…
- 2026-05-11 — Emcure Pharmaceuticals Limited reported strong financial results for Q4 FY26, achieving a revenue growth of 16.6% year-o…
See EMCURE's full Research Pro page — annual report summary, insider trades, promoter pledge trend, options positioning and Ask-RedixFi AI.
Sign up free